Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with apatinib mesylate for head and neck squamous cell carcinoma is ongoing with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN